Octreotide Sandoz

Octreotide, the active ingredient in Octreotide Sandoz, is a somatostatin analog presented as a strength/form for injection use. It treats hormone‑secreting tumors and related endocrine disorders in adults and children. GNH USA supplies Octreotide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

GNH USA supplies Octreotide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Octreotide Sandoz is a somatostatin analogue that modulates hormone secretion in several endocrine conditions.

- Acromegaly: reduces growth hormone and IGF‑1 levels, helping control disease activity. - Neuroendocrine tumors: controls symptoms related to hormone over‑production such as flushing and diarrhoea. - Carcinoid syndrome: decreases flushing, wheezing and diarrhoea associated with serotonin excess. - Vaso‑occlusive crises in sickle cell disease (investigational): may reduce the frequency of painful episodes. - Prevention of postoperative pancreatic fistula: lowers pancreatic secretions after major abdominal surgery.

Octreotide may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal cramping - Injection site reactions: erythema, pain, induration - Gallbladder abnormalities: biliary sludge or stones - Metabolic changes: hyperglycaemia or hypoglycaemia - Fatigue or headache

Serious or Rare Side Effects: - Pancreatitis - Severe hyperglycaemia requiring insulin therapy - Cardiac arrhythmias - Acute gallbladder disease requiring surgery - Anaphylactic reactions

Octreotide should be used with careful clinical monitoring and appropriate patient education.

- Dose adjustment: renal or hepatic impairment may require lower doses. - Glycaemic monitoring: patients with diabetes may experience altered blood glucose levels. - Gallbladder monitoring: long‑term therapy can promote biliary sludge formation. - Cardiovascular assessment: monitor for bradyarrhythmias in patients with pre‑existing conduction disorders. - Pregnancy and lactation: only use if the potential benefit outweighs risk; discuss with a specialist. - Store at ambient temperature: keep in original container, protect from light and moisture.

Octreotide can interact with several drug classes, affecting absorption, metabolism, or therapeutic outcomes.

Major Interactions (Avoid): - Short‑acting somatostatin analogues: concurrent use may amplify hormonal suppression. - Cytochrome P450 inducers: may reduce octreotide plasma concentrations.

Moderate Interactions (Monitor Closely): - Insulin and oral hypoglycaemic agents: risk of hypoglycaemia or hyperglycaemia. - Antiplatelet or anticoagulant drugs: increased risk of gallbladder‑related bleeding. - Proton pump inhibitors: may alter gastrointestinal absorption of the drug. - Diuretics: potential electrolyte disturbances when combined with octreotide‑induced fluid shifts. - Radiolabelled somatostatin analogues for imaging: timing adjustments may be required to avoid diagnostic interference.